Contraception News and Research RSS Feed - Contraception News and Research

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
Smartphone app helps increase contraceptive use among married rural women in India

Smartphone app helps increase contraceptive use among married rural women in India

A smartphone app containing motivational videos developed to help married rural women in India better understand contraceptive choices led to a dramatic increase in the number of women using modern family planning methods in just a few months, new Johns Hopkins Center for Communication Programs (CCP) research suggests. [More]
Estrogen helps women fight flu virus better than men

Estrogen helps women fight flu virus better than men

Estrogen dramatically reduced the amount of flu virus that replicated in infected cells from women but not from men, a new study by researchers at the Johns Hopkins Bloomberg School of Public Health shows. [More]
Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. [More]
Incorporating postpartum contraceptive services across the continuum of reproductive healthcare

Incorporating postpartum contraceptive services across the continuum of reproductive healthcare

Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health risks has emerged in the past few decades and, after a period of neglect, interest in postpartum family planning has followed, supported by organizations like WHO and USAID. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). [More]
Researchers examine risk of four common types of ovarian cancer in women with different childbearing patterns

Researchers examine risk of four common types of ovarian cancer in women with different childbearing patterns

The more children a woman has or whether a woman has had her fallopian tubes cut lowers the risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 National Cancer Research Institute Cancer Conference today (Tuesday). [More]
Impact of physicians' unconscious attitudes toward disabled and LGBT patients

Impact of physicians' unconscious attitudes toward disabled and LGBT patients

Physicians' unconscious attitudes toward special patient populations like disabled and LGBT patients may be partially responsible for poorer overall health observed in these communities, according to a Rowan University professor of family medicine. [More]
Osteopathic physicians, researchers to present clinical and research updates at OMED 15

Osteopathic physicians, researchers to present clinical and research updates at OMED 15

Osteopathic physicians, researchers and aligned medical professionals will present clinical and research updates in 15 specialties at OMED 15 in Orlando October 17-21. [More]
Research shows more than 30,000 women die from cardiovascular disease in UK

Research shows more than 30,000 women die from cardiovascular disease in UK

More than 30,000 women die from coronary heart disease in the UK every year with over 700,000 women living with the consequences of heart disease and stroke, according to research published by The British Heart Foundation ahead of World Heart Day on 29th September. [More]
Johns Hopkins study highlights need for effective postpartum interventions for women with pregnancy complications

Johns Hopkins study highlights need for effective postpartum interventions for women with pregnancy complications

Citing an analysis of more than 26,000 Maryland Medicaid claims, Johns Hopkins researchers report evidence that poor women with recent complications during their pregnancies are using the emergency room at higher rates after delivery and may not be getting the postpartum care and follow-up they need to prevent further health problems. [More]
FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. [More]
Report: Birth control pills cause significant increase in stroke risk

Report: Birth control pills cause significant increase in stroke risk

Birth control pills cause a small but significant increase in the risk of the most common type of stroke, according to a comprehensive report in the journal MedLink Neurology. [More]
Pregnant teenagers at higher risk of more pregnancies in teenage years

Pregnant teenagers at higher risk of more pregnancies in teenage years

Nearly a quarter of teenagers in England and Wales who have had an abortion have been pregnant before, according to new research from the University of East Anglia. [More]
Researchers discover new strategy for attacking cancer cells

Researchers discover new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. [More]
UVA researchers identify new strategy for attacking cancer cells

UVA researchers identify new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments. [More]
Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome that causes major disruption in several areas of life for many women. Many treatment options have been proposed, but which are most effective? A comprehensive review of the evidence, including specific treatment guidelines, is presented in the September Journal of Psychiatric Practice, published by Wolters Kluwer. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Advertisement
Advertisement